Novanta
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.0 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 127.71% +4.00pp
- Institutions
- 473 -3
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Robert Buckley | Chief Financial Officer | 0.35% |
| Matthijs Glastra | Chairperson & CEO | 0.22% |
| Charles Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | 0.04% |
| John Burke | Chief Accounting Officer | 0.02% |
| Lonny Carpenter | Lead Independent Director | 0.02% |
| Maxine Mauricio | Independent Director | 0.01% |
| Frank Wilson | Independent Director | 0.01% |
| Darlene J. Solomon | Independent Director | 0.01% |
| Robert Johnson | Independent Director | 0.01% |
| John Lesica | Co-Chief Operating Officer of Medical Solutions | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | Matthew Farrell | Independent Director | Derivative Exercise and Retained | +241 | -- |
| 2026-09-10 | Thomas Secor | Independent Director | Automatic Disposition | -663 | $147.60 |
| 2026-07-01 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -6,500 | $160.13–164.20 |
| 2026-06-01 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -6,500 | $164.61–171.28 |
| 2026-06-01 | Matthijs Glastra | Chairperson & CEO | Intent to Sell (Form 144) | -6,500 | -- |
| 2026-05-11 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -7,500 | $150.00–151.34 |
| 2026-05-04 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -6,500 | $130.59–133.27 |
| 2026-04-16 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -6,500 | $130.05 |
| 2026-03-15 | Robert Buckley | Chief Financial Officer | Derivative Exercise and Sale | -9,957 | $14.13–118.80 |
| 2026-03-01 | Matthijs Glastra | Chairperson & CEO | Automatic Disposition | -6,500 | $131.92–140.48 |
| 2026-02-23 | Matthijs Glastra | Chairperson & CEO | Derivative Exercise and Sale | -5,247 | $137.44 |
| 2026-02-23 | Matthijs Glastra | Chairperson & CEO | Derivative Exercise and Retained | +5,605 | -- |
| 2026-02-23 | Robert Buckley | Chief Financial Officer | Derivative Exercise and Sale | -2,624 | $137.44 |
| 2026-02-23 | Robert Buckley | Chief Financial Officer | Derivative Exercise and Retained | +2,802 | -- |
| 2026-02-23 | Charles Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | Derivative Exercise and Sale | -243 | $137.44 |
| 2026-02-23 | Charles Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | Derivative Exercise and Retained | +582 | -- |
| 2026-02-23 | John Burke | Chief Accounting Officer | Derivative Exercise and Sale | -141 | $137.44 |
| 2026-02-23 | John Burke | Chief Accounting Officer | Derivative Exercise and Retained | +338 | -- |
| 2026-02-22 | Charles Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | Derivative Exercise and Sale | -311 | $142.38 |
| 2026-02-22 | Charles Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | Derivative Exercise and Retained | +748 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Novanta discussion 0 comments